Federal Register Notice: FDA seeks comments on the current burden hours on regulated industry of complying with the guidance, Waiver of In Vivo Demonstration of Bioequivalence of Animal Drugs in
Soluble Powder Oral Dosage Form Products and Type A Medicated Articles — 21 CFR 514.1(b)(7-8). Comments should be submitted by 3/13. To view this notice, click here.
